Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CV 9202

Drug Profile

CV 9202

Alternative Names: BI 1361849; CV-9202

Latest Information Update: 29 Jan 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CureVac; Ludwig Institute for Cancer Research
  • Developer Boehringer Ingelheim; Cancer Research Institute; CureVac; Ludwig Institute for Cancer Research
  • Class Cancer vaccines; RNA vaccines
  • Mechanism of Action Immunostimulants; Toll-like receptor 7 modulators; Toll-like receptor 8 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-small cell lung cancer

Most Recent Events

  • 24 Jan 2018 CureVac has patent protection for CV 9202 in Europe
  • 02 Jun 2017 Ludwig Institute for Cancer Research, Cancer Research Institute, Boehringer Ingelheim, MedImmune, CureVac and PharmaJet plan a phase I/II trial for Non-small cell lung cancer (Metastatic disease, Combination therapy, Second-line therapy or greater) in USA (NCT03164772)
  • 20 Jan 2017 Phase-I/II clinical trials in Non-small cell lung cancer (Combination therapy) in USA (Intradermal) (NCT03164772)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top